Karyopharm Therapeutics(KPTI) - 2024 Q3 - Quarterly Results

EXHIBIT 99.1 BELIEVERS IN THE EXTRAORDINARY Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress – Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve Myelofibrosis (MF); Expecte ...